C
andida species are part of the normal human skin and mucous membrane microflora. However, these yeasts may also represent important pathogens causing opportunistic infections of increasing frequency in specific populations. According to the Hospital Infection Program released from the Centers for Disease Control and Prevention, the incidence of fungal infections increased between 1980 and 1990 from 2.0 to 3.8 infections per 1,000 discharges, including a significant increase of candidemia (1) . Candida species are more commonly isolated from patients of burn or trauma intensive care units (ICUs) and patients with abdominal surgery, hematologic malignancies, and solid organ and bone marrow transplantation (1) . More specifically, Candida spp are the fourth more common pathogen isolated from blood in surgical intensive care unit (SICU) patients (2) . Furthermore, the development of such infections is associated with increased overall and attributable mortality (ranging in different studies from 20% to 85% and from 30% to 60%) and with morbidity, which lengthens the duration of ICU stay and increases the cost of hospitalization (2) .
Many risk factors contributing to the development of fungal infections in SICU and other high-risk patients have been identified (3); however, their predictive value remains unclear. Among them, prior colonization with Candida spp appears to be of special importance, since the colonizing and the offending fungus are identical in 84 -94% of cases (4, 5) , and the probability of Candida spp infection in the absence of previous colonization is very low (negative predictive value 94 -100%). In addition, the symptoms and signs of fungal infections are nonspecific, and the available microbiological (including blood cultures) and imaging tests for early diagnosis usually do not provide a definite diagnosis (6, 7) .
Prophylaxis with antifungal regimens has been proposed as an effective (and probably cost-effective) approach to prevent such infections in high-risk patients (8). Azoles and polyenes were used in a number of randomized controlled trials to assess their effectiveness as prophylactic regimens. Azoles are associated with fewer adverse effects compared with polyenes and can be administered orally. On the other hand, azoles are suspected of contributing to selection of resistant Candida isolates and a shift toward wild non-albicans species (1, 9) . In most studies, the use of a prophylactic regimen led to a decrease of opportunistic fungal infections, whereas the effect on mortality was not resolved. We performed a metaanalysis of randomized controlled trials (RCTs) in a defined patient population, namely SICU patients, to reassess their safety and effectiveness on a bigger scale and clarify the issue of mortality. 
METHODS

Data Sources
Selection of Randomized Controlled Trials
Two independent reviewers performed a literature search and examined the identified RCTs for further evaluation of data on safety, effectiveness, and mortality. A study was considered eligible if a) it was a randomized, placebo-controlled clinical trial; b) it focused on the role of azole antifungal regimens as prophylaxis against fungal infections (mainly against Candida), in high-risk, surgical ICU patients; and c) it assessed the effectiveness and/or toxicity of triazoles as well as mortality. No restriction in language was set. Both blind and nonblind RCTs were included in the analysis. RCTs focusing on pharmacokinetic and/or pharmacodynamic variables were excluded. RCTs studying the effect of azole derivatives on adrenal hormone production and RCTs in which the azoles were used for preemptive or early empirical therapy were also excluded. RCTs using antifungal prophylaxis with amphotericin B and/or nystatin (liposomal or not, alone or in combination with other antifungal agents, systemic or topical, or as part of a regimen for selective bowel decontamination) or comparing a polyene with an azole antifungal agent were considered ineligible for the present meta-analysis.
Definitions
Fungal Infections. The definitions of the various types of fungal infections (candidemia, nonbloodstream invasive fungal infections, and superficial fungal infections [skin or mucosal]) were based on the definitions provided in the reported RCTs. In brief, candidemia was defined as the isolation of a Candida species in at least one blood culture. An invasive fungal infection diagnosis required positive histologic findings from deep tissues, with or without clinical symptoms, signs, or radiologic lesions suggestive of this type of infection. The isolation of Candida species from a biopsy specimen from the peritoneal cavity or the peritoneal fluid and clinical evidence of infection were necessary for the diagnosis of intraabdominal candidiasis. Noninvasive (superficial) fungal infections were defined as infections with clinical symptoms and/or signs of oral, esophageal (without histologic proof for invasive candidiasis), superficial wound, lower urinary tract, and vaginal candidiasis, with positive cultures of specimens from the site of infection.
High-and Low-Risk Patients. Medical or surgical patients having three or more risk factors associated with fungal infections were considered high risk for the development of such an infection, whereas those with two or fewer risk factors were considered low-risk patients. Patients undergoing transplantation were considered high risk for the development of fungal infections if they were expected to stay in the ICU for Ͼ5 days following the operation.
Adverse Effects. No specific definitions were reported for various types of drug toxicity, including nephrotoxicity and hepatoxicity, in most of the analyzed RCTs, although numerical data about drug toxicity were provided in some of them. Hepatotoxicity was defined as elevation of liver function tests more than five times than the upper normal limit in one of the RCTs.
Data Extraction
The following data were extracted from each study: year of publication, clinical setting, patient population, numbers of patients, antifungal agents and doses used, clinical and microbiological outcomes, toxicity, statements of the authors concerning the development of resistant Candida species or a shift toward colonization or infection from non-albicans species, and mortality. Data were extracted by two independent reviewers. Any disagreement between the two reviewers was resolved by consensus meetings of the authors.
Outcomes
The development of fungal infections, allcause mortality, and adverse effects due to study regimens were considered as primary outcome measures for the present meta-analysis. Development of fungal infections was further analyzed using four different outcome measures as defined previously: candidemia, nonbloodstream invasive fungal infections, and noninvasive (superficial) fungal infections. Mortality was also analyzed in the subset of studies that included exactly the same study azole and the same patient population. All-cause mortality was analyzed based on the reported data for mortality during the study period.
Data Analysis
Statistical analyses were performed using the Meta-analyst software (Joseph Lau, Tufts University School of Medicine, Boston, MA). The heterogeneity between RCTs was assessed by using a chi-square test; p Ͻ .10 was defined to note statistical significance in the analysis of heterogeneity. Publication bias was assessed by the funnel plot method using Egger's test. Pooled odds ratios (OR) and 95% confidence intervals (CI) for all primary and secondary outcomes were calculated, using both the Mantel-Haenszel fixed effects and the DerSimonian-Laird random effects models. Results from the fixed effects model are presented only when no heterogeneity between RCTs was observed; otherwise results from the random effects model are presented.
RESULTS
Randomized Controlled Trials
We identified 45 published RCTs, performed on medical and surgical ICU patients at risk of fungal infections. Of those RCTs, 18 were excluded because amphotericin B or nystatin was used as part of a selective bowel decontamination regimen (10 -27), six because amphotericin B or nystatin alone or in combination with other antifungal agents was compared with various antifungal agents including azoles or the lipid forms of amphotericin B (28 -33), three because amphotericin B or nystatin was compared with placebo or no drug (34 -36) , three because they compared the effectiveness of azole derivatives against placebo in nonsurgical, non-ICU patients (37) (38) (39) , and three because they compared azoles with placebo in preterm, low-weight infants (40 -42) . In addition, one RCT was excluded because one perioperative dose of fluconazole was used as prophylaxis (43) , one because the primary outcome was the Candida colonization and/or infection of prosthetic devices in postlaryngectomy patients under prophylaxis with fluconazole (44), one because it compared the effectiveness of prophylactic itraconazole vs. fluconazole (45) , one because it was conducted in a mixed lowand high-risk patient population and it was not placebo controlled (46) , and one because it was performed in low-risk surgical patients (47) .
In Figure 1 , we present a flow diagram describing the selection process applied to identify the pool of RCTs used in the final analysis. An RCT that studied the value of antifungal prophylaxis in surgical ICU patients with septic shock due to bacterial pathogens (48) was used only in the secondary analysis, together with the other six RCTs of the main analysis (49 -54) , since septic shock represents a special condition. This is mainly because the patients enrolled in this RCT already had an established serious bacterial infection leading to septic shock, whereas the patients enrolled in the other RCTs that were included in our meta-analysis had several risk factors for fungal infections but septic shock was not an inclusion criterion. Two of the included RCTs reported results of both medical and surgical patients: Garbino et al. (50) with 62% surgical patients and Pelz et al. (51) with 92% surgical patients.
The main characteristics of all RCTs used in the meta-analysis are shown in Table 1. Risk factors for fungal infections that were commonly present in patients enrolled in the RCTs that were included in our meta-analysis were fungal colonization before enrollment, diabetes, solid tumors, abdominal surgery, presence of central and peripheral venous catheters for Ͼ3 days, exposure to antibiotics, and intubation or mechanical ventilation. The duration of hospitalization and ICU stay varied in the different RCTs; however, there was no imbalance between the compared treatment groups in the individual RCTs. There was also no difference in the severity of the underlying disease between patients in the prophylaxis or the placebo group, based on the reported data, including Acute Physiology and Chronic Health Evaluation II and III scores. No publication bias was found by the funnel plot method using Egger's test.
Administration of Study Drugs
Azoles as antifungal prophylaxis were administered either intravenously or orally. Fluconazole was administered intravenously in two RCTs and orally in one RCT, whereas in one RCT it was administered intravenously before the operation and switched to oral administration at a later stage. The dosages of the administered drugs are shown in Table 1 . The duration of administration of antifungal prophylaxis or placebo varied in different RCTs, but there was no statistical difference in duration of therapy between the compared treatment groups in the individual RCTs. When itraconazole (49) or ketoconazole (54) was administered, plasma levels were measured to verify the absorption of the prophylactic medications; effective plasma levels were achieved (Ͼ0.25 mg/L for itraconazole and Ͼ5 mg/L for ketoconazole) in most of the patients.
Development of Fungal Infections
Outcome data from the selected RCTs are presented in Table 2 . Data on the development of fungal infections were reported in all RCTs. Antifungal prophylaxis with azoles, compared with placebo, was significantly associated with fewer fungal infections (816 patients, fixed effects model, OR ϭ 0.20, 95% CI 0.13-0.32). Odds ratios for the development of invasive fungal infections and candidemia in individual RCTs as well as the pooled odds ratio are presented in Figure 2 . The 
Mortality
All-cause mortality during the whole study period (based on the reported data) was available in four RCTs. In two additional RCTs, only the deaths occurring during the ICU stay were reported. In Figure 3 we present data from individual RCTs as well as pooled data on mortality. Mortality in high-risk patients receiving azoles as anti-fungal prophylaxis was not lower compared with placebo recipients (847 patients, fixed effects model, OR ϭ 0.74, 95% CI 0.52-1.05). The same result was also observed in subgroup analyses, in which fluconazole was used as antifungal prophylaxis (50 -53) (719 patients, fixed effects model, OR ϭ 0.81, 95% CI 0.56 -1.18), and for RCTs not conducted in transplant recipients (50, 51, 53, 54) (564 patients, fixed effects model, OR ϭ 0.80, 95% CI 0.54 -1.19). A subset analysis conducted on RCTs using only surgical patients (49, (51) (52) (53) (54) also showed that azole prophylaxis was not associated with a reduction in mortality (643 patients, fixed effects model, OR ϭ 0.64, 95% CI 0.41-1.01). Finally, a meta-analysis after incorporating one RCT with prophylactic use of fluconazole in ICU patients with septic shock due to bacteria (48) showed that azole prophylaxis was associated with a statistically significant reduction in overall mortality (918 patients, fixed effects model, OR ϭ 0.68, 95% CI 0.49 -0.95).
Adverse Effects-Development of Resistance
Numerical data regarding adverse effects were reported in three RCTs (49, 52, 53) . The use of antifungal prophylaxis with azoles was associated with more adverse effects; however, this finding was 
Sensitivity Analyses
An additional analysis was conducted excluding the RCTs conducted on transplant recipients and patients with recurrent gastrointestinal perforations or anastomotic leakages. Three RCTs were included in this subset analysis; a reduction in fungal infections was observed after the administration of azoles as prophylaxis (499 patients, random effects model, OR ϭ 0.30, 95% CI 0.16 -0.58). No statistically significant differences were found regarding invasive fungal infections (499 patients, fixed effects model, OR ϭ 0.38, 95% CI 0.10 -1.41) and mortality (521 patients, fixed effects model, OR ϭ 0.86, 95% CI 0.56 -1.30).
A second sensitivity analysis was conducted after the exclusion of the RCT by Garbino et al. (50) , in which selective bowel decontamination was also administered. The administration of antifungal prophylaxis was associated with a statistically significant reduction in the development of fungal infections (612 patients, random effects model, OR ϭ 0.18, 95% CI 0.10 -0.33) and severe fungal infections (612 patients, random effects model, OR ϭ 0.18, 95% CI 0.11-0.31).
DISCUSSION
The results of our meta-analysis suggest that the use of azoles as antifungal prophylaxis in high-risk patients in the SICU is associated with fewer fungal infections but appears not to be associated with lower overall mortality rate. Our study provides clinically useful information, since the results include point estimates of the effect of antifungal prophylaxis on several outcomes, including mortality, with narrower confidence intervals compared with the results of the individual studies. All outcomes related to the occurrence of fungal infections were fewer among patients receiving azole prophylaxis. Specifically, candidemia, nonbloodstream invasive fungal infections, superficial fungal infections, and total fungal infections (invasive and superficial) were all lower among patients receiving antifungal prophylaxis. A similar result was also observed in the sensitivity analyses (after the exclusion of transplant recipients and patients with gastrointestinal perforations or after the exclusion of nonsurgical patients). Of importance, mortality rate was not reduced in our primary analysis as well as in secondary analyses when using RCTs performed on patients receiving fluconazole prophylaxis, RCTs excluding transplant patients, and/or RCTs using selective bowel decontamination. However, the addition of one RCT with bacterial septic shock patients showed that azole prophylaxis appeared to be associated with better survival rate (p ϭ .02). Also, a reduction of fungal colonization was observed with the use of antifungal prophylaxis.
We acknowledge that our meta-analysis is not without limitations. First, the RCTs used in our meta-analysis were conducted during a prolonged period of time (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) . Subsequently, the management of the underlying diseases and the susceptibility of the isolated Candida strains as well as the mixture of different fungal species may have undergone several changes during this period. Second, the patient populations included are not homogeneous, since both transplant and nontransplant patients were incorporated in the analysis. In addition, a small proportion of the enrolled patients in two of the six RCTs used had not undergone any operation. However, separate analyses after the exclusion of RCTs that enrolled transplant recipients or nonsurgical patients did not substantially alter the results. Third, the azole used was not the same in all RCTs. Fluconazole, itraconazole, and ketoconazole were used as the prophylactic regimen in different RCTs. In addition, the daily dosage and the route of administration of fluconazole were not identical. The dose of fluconazole varied from 100 to 400 mg daily, and it was given orally or intravenously. Unfortunately, the available data do not provide enough conclusive evidence regarding the minimum dosage of various antifungal agents, including azoles, that is sufficient for prophylaxis. Fourth, there was a variation in the duration of antifungal prophylaxis used in different RCTs.
Also, we acknowledge that the RCTs included in our meta-analysis were not designed to specifically identify risk factors for the development of fungal infections among SICU patients. However, we selected only those RCTs that included patients with several risk factors (as identified by other investigators) for the development of fungal infections. In addition, the definitions of fungal infections in the RCTs included in our metaanalysis were not in accordance with the definitions of the European Organization for Research and Treatment of Cancer (55) , because all of them were designed before the introduction of these definitions to the literature in 2002. More spe- cifically, none of the RCTs provided data specifically for proven, probable, and possible fungal infections; data regarding invasive and superficial fungal infections were provided in all included studies, whereas data on proven and suspected fungal infections were provided in the studies by Sharpe et al. (49) and Pelz et al. (51) . Therefore, we could not differentiate between proven, probable and possible fungal infections. Of note, data about drug toxicity were reported only in three of seven RCTs, and in these studies no specific definitions of various types of adverse events were reported; the reporting of only limited data regarding drug toxicity is unfortunately common in published papers reporting results of RCTs. Another limitation is that the development of antifungal resistance was not the focus of the analyzed RCTs and, thus, it was not examined systematically in the studies included in our meta-analysis. Finally, although quality assessment of the studies was not performed, all included studies were double-blind, placebocontrolled RCTs (except for one RCT that was not a double-blind study).
The effectiveness of antifungal prophylaxis is debated in most patient populations. A meta-analysis on antifungal prophylaxis for transplant recipients reported that fluconazole was effective in reducing invasive and superficial fungal infections but not mortality (56) . Data from RCTs using other azoles as antifungal prophylaxis were not conclusive regarding either invasive fungal infections or mortality (56) . When all antifungal regimens (azoles and polyenes) used in RCTs of solid organ transplant recipients were analyzed together, a reduction in invasive and superficial fungal infections was noted, but mortality was not reduced (56) . In another meta-analysis, conducted on RCTs with neutropenic patients, it was reported that although prophylaxis contributed to a reduction of fungal infections, mortality remained unaffected, whereas only specific subgroups of patients (patients with prolonged neutropenia or undergoing allogeneic hemopoietic stem cell transplantation or patients receiving high daily doses of antifungal agents for prophylaxis) would benefit (57) . Also, in another meta-analysis of RCTs of neutropenic patients it was reported that oral fluconazole prophylaxis was beneficial in reducing invasive fungal infections in patients undergoing bone marrow transplantation but not in patients who were not undergoing bone marrow transplantation (58) .
Our meta-analysis was purposely restricted to RCTs that included high-risk surgical patients. This strategy was selected because not all patients undergoing operations or in need for ICU care have the same probability for the development of fungal infections. Many risk factors for the development of such infections among patients treated in the ICU have been identified; however, each factor alone does not contribute significantly to increased mortality (3, 59) . On the contrary, the combination of several risk factors predisposes to worse outcomes (3). In addition, the inclusion of RCTs with low-risk patients in the present metaanalysis would increase the heterogeneity of the analyzed patients and therefore the possibility for statistical errors.
Superficial fungal infections, although easy to treat, are a problem that affect quality of life. Invasive fungal infection is a serious and potentially fatal condition, with increasing frequency in high-risk medical and surgical patients. Furthermore, there are important considerations related to the effect of fungal infections on the length of hospitalization and the cost of health care. Although the incidence of invasive fungal infections can be reduced in high-risk medical and surgical patients by prophylactic or preemptive administration of antifungal agents (by both polyenes and azoles), as indicated in a number of RCTs (35, 36, 44, 48, (51) (52) (53) 60) , the economic aspects of the use of such prophylactic or preemptive antifungal strategies have not been systematically evaluated. Two recent developments are related to the control of fungal infections, namely the decrease in the price of fluconazole since the availability of generic forms of the drug and the introduction of echinocandins that may have a significant impact on financial analyses regarding the prevention and treatment of fungal infections. Subsequently, these interventions deserve further study, including cost-effectiveness analyses in various populations.
Azoles represent a more attractive approach because they are administered orally. However, the possibility of administering azoles by mouth as prophylactic agents against invasive fungal infections is not so important in the population studied in this meta-analysis; it is true that in SICU patients the absorption after oral administration of various medications may be compromised due to bowel edema. In addition, the bioavailability of oral administration of azoles, mainly itraconazole and ketoconazole, is frequently impaired by several comorbidity factors and concomitantly administered medications that may lead to differences in the effect on clinically important outcomes. Subsequently, intravenous administration of antifungal prophylaxis may be a better option in this population.
A recent advance in the field of mycology that may affect clinical practice is the development of several newer molecular diagnostic tests for fungal infections (such as the detection of fungal DNA and antigens like galactomannan and glucan). The widespread use of these tests may change several aspects of the management of fungal infections in various populations including high-risk SICU patients. However, it is unclear how these developments may change the practice of antifungal prophylaxis (61) .
Another important and intensely debated issue regarding the use of prophylactic antifungal agents is the development of resistant Candida strains or the selection of resistant Candida species under antifungal drug pressure. Especially, fluconazole was accused of the selection of such species (mainly Candida krusei and Candida glabrata) in retrospective studies (62, 63) . Only four of the RCTs included in this meta-analysis reported whether an increase in the incidence of resistant species was observed (50 -53) . Although no specific microbiological data were reported, in these four RCTs there was little evidence that the azole prophylaxis was associated with emergence of resistant fungal strains or a shift toward non-albicans species. However, the number of infections as well as the number of isolated fungi in patients in the analyzed RCTs are too small to provide sufficient information on these important issues.
These observations regarding the emergence of resistant Candida species are in keeping with the results of three other meta-analyses (in transplant recipients and neutropenic patients), which did not associate the emergence of resistant species to antifungal prophylaxis alone (59, 60, 61) . In addition, the fact that C. krusei and C. glabrata exhibit innate resistance to fluconazole, the azole most widely used for antifungal prophylaxis, supports the previous findings (61, 64, 65) . Furthermore, there are other factors that can explain, in part, the shift toward non-albicans species that was observed during the last decade, such as the more intense and aggressive management of the underlying disease (63, (65) (66) (67) , the neutrophil count of treated patients (63) , and the simultaneous prophylactic use of antibiotics (mainly quinolones, as well as other broad-spectrum antibiotics) (63, 68) .
CONCLUSIONS
Despite its limitations, we believe that our meta-analysis offers clinically useful information regarding the controversial issue of antifungal prophylaxis in SICU patients. A clinical trial with a very large number of patients is still needed to obtain a definitive answer on the value of antifungal prophylaxis with azoles in high-risk SICU patients, although such a trial is unlikely to be done soon. Subsequently, the results of our meta-analysis may be useful because they help clarify further the effect of azole prophylaxis in this population. Specifically, our data indicate the reduction of fungal infections and subsequently provide support for the use of azoles as antifungal prophylaxis in this defined population, namely high-risk SICU patients. However, the possible benefit of prophylaxis should be weighed against the considerable possible drawbacks such as the emergence of resistance, the selection of non-albicans strains, and drug-related toxicity. 
